Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
La Jolla Pharmaceutical's Business Segments
La Jolla Pharmaceutical's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 11
Regions Reported
-
Revenue by Product & Service Category -
- Product99.7%
- License and Other Revenue0.3%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 11 | 99.7% |
| License and Other Revenue | $ 0 | 0.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, also known as La Jolla Pharma, is a biopharmaceutical company headquartered in San Diego, California. It focuses on the development and commercialization of innovative therapies for life-threatening diseases, particularly in the areas of kidney disease and sepsis.
The company was founded in 1989 under the name Prometheus Laboratories Inc., and after several changes in ownership and rebranding, it became La Jolla Pharmaceutical Company in 2012. Over the years, La Jolla Pharma has established itself as a leader in the field of critical care medicine, with a strong emphasis on improving patient outcomes and addressing unmet medical needs.
One of the company's notable achievements is the development of a proprietary formulation of Angiotensin II, a hormone that plays a crucial role in regulating blood pressure and fluid balance in the body. This formulation, known as LJPC-501, has shown promising results in clinical trials for the treatment of hypotension, a condition characterized by dangerously low blood pressure. The drug was granted fast-track designation by the U.S. Food and Drug Administration (FDA) and received regulatory approval in 2017 under the brand name Giapreza.
La Jolla Pharma is also focused on developing therapies for the treatment of septic shock, a severe condition resulting from bacterial infection that can lead to organ failure and death. The company's lead candidate in this area is LJPC-0118, a novel peptide antagonist of the C-C Chemokine Receptor 9 (CCR9) pathway. This drug is currently in clinical trials and has shown promising results in preclinical studies.
In addition to its core therapeutic areas, La Jolla Pharma also has a dedicated research and development team working on various other projects, including the development of small molecules for the treatment of chronic kidney disease and other inflammatory disorders.
The company has established collaborations with leading academic institutions, medical centers, and pharmaceutical partners to enhance its research capabilities and accelerate the development of its pipeline products. These collaborations have allowed La Jolla Pharma to leverage the expertise of key opinion leaders in various therapeutic areas and streamline the regulatory and commercialization process.
La Jolla Pharmaceutical Company is committed to conducting cutting-edge research, maintaining high-quality manufacturing standards, and ensuring patient safety. It has a robust portfolio of intellectual property, with numerous patents and patent applications covering its products and technologies. The company's success is driven by its dedicated team of scientists, clinicians, and professionals who work tirelessly to bring innovative therapies to patients in need.
Overall, La Jolla Pharmaceutical Company is a leading biopharmaceutical company that specializes in the development and commercialization of advanced therapies for life-threatening conditions. It has a strong pipeline of promising products, a commitment to scientific excellence, and a focus on improving patient outcomes.
The company was founded in 1989 under the name Prometheus Laboratories Inc., and after several changes in ownership and rebranding, it became La Jolla Pharmaceutical Company in 2012. Over the years, La Jolla Pharma has established itself as a leader in the field of critical care medicine, with a strong emphasis on improving patient outcomes and addressing unmet medical needs.
One of the company's notable achievements is the development of a proprietary formulation of Angiotensin II, a hormone that plays a crucial role in regulating blood pressure and fluid balance in the body. This formulation, known as LJPC-501, has shown promising results in clinical trials for the treatment of hypotension, a condition characterized by dangerously low blood pressure. The drug was granted fast-track designation by the U.S. Food and Drug Administration (FDA) and received regulatory approval in 2017 under the brand name Giapreza.
La Jolla Pharma is also focused on developing therapies for the treatment of septic shock, a severe condition resulting from bacterial infection that can lead to organ failure and death. The company's lead candidate in this area is LJPC-0118, a novel peptide antagonist of the C-C Chemokine Receptor 9 (CCR9) pathway. This drug is currently in clinical trials and has shown promising results in preclinical studies.
In addition to its core therapeutic areas, La Jolla Pharma also has a dedicated research and development team working on various other projects, including the development of small molecules for the treatment of chronic kidney disease and other inflammatory disorders.
The company has established collaborations with leading academic institutions, medical centers, and pharmaceutical partners to enhance its research capabilities and accelerate the development of its pipeline products. These collaborations have allowed La Jolla Pharma to leverage the expertise of key opinion leaders in various therapeutic areas and streamline the regulatory and commercialization process.
La Jolla Pharmaceutical Company is committed to conducting cutting-edge research, maintaining high-quality manufacturing standards, and ensuring patient safety. It has a robust portfolio of intellectual property, with numerous patents and patent applications covering its products and technologies. The company's success is driven by its dedicated team of scientists, clinicians, and professionals who work tirelessly to bring innovative therapies to patients in need.
Overall, La Jolla Pharmaceutical Company is a leading biopharmaceutical company that specializes in the development and commercialization of advanced therapies for life-threatening conditions. It has a strong pipeline of promising products, a commitment to scientific excellence, and a focus on improving patient outcomes.
La Jolla Pharmaceutical Company is a biopharmaceutical firm that specializes in the discovery, development, and commercialization of innovative therapies for patients with life-threatening diseases. The companys focus is primarily on developing solutions in critical therapeutic areas, with a well-defined pipeline of products and a range of services that facilitate the progression from concept to market. Below is an extensive overview of the segments, products, and services that define the company’s offerings.
Segments and Products
1. GIAPREZA® (Angiotensin II)
GIAPREZA® is La Jollas flagship product and is significant in the companys portfolio. This FDA-approved medication is a potent vasoconstrictor indicated specifically for treating adult patients experiencing septic shock or other forms of distributive shock. Administered via intravenous infusion, GIAPREZA® operates by increasing blood pressure in critically ill patients, thereby addressing a crucial medical need.
Mechanism of Action:
GIAPREZA® acts as an angiotensin II receptor agonist, which leads to vasoconstriction, enhancing blood flow to vital organs and potentially reducing mortality rates among patients suffering from severe hypotension.
LJPC-0118
Currently in clinical development, LJPC-0118 targets severe malaria, a disease that poses significant mortality risk, particularly in endemic regions. This product is part of La Jollas effort to meet the urgent medical needs in areas where malaria remains a critical health challenge.
Clinical Potential:
LJPC-0118 aims to improve treatment outcomes for patients suffering from severe malaria, which is characterized by high mortality rates and challenges in effective management.
Other Pipeline Products
La Jolla Pharmaceutical Company is actively engaged in expanding its pipeline beyond GIAPREZA® and LJPC-0118. Notable candidates include:
- LJPC-401: This investigational therapy focuses on conditions associated with iron overload, which can lead to severe health complications if not managed appropriately. The drug seeks to provide effective management options for autoimmune and chronic diseases characterized by excess iron levels.
- LJPC-30SA: Also centered around the treatment of severe malaria, LJPC-30SA is being investigated for its potential to increase survival rates in patients with this life-threatening infection.
- LJPC-0119: Targeting chronic kidney disease, LJPC-0119 seeks to address a significant area of unmet medical need, as chronic kidney disease affects millions globally and often leads to end-stage renal failure.
Services
La Jolla Pharmaceutical Company offers a suite of services that support the entire lifecycle of product development and commercialization:
1. Clinical Development
The company undertakes comprehensive clinical trials to evaluate the safety and efficacy of its products. This includes:
- Protocol Design: Crafting detailed clinical protocols that outline the methodology, objectives, and statistical analysis plan.
- Patient Recruitment and Monitoring: Identifying and enrolling eligible patients while continuously monitoring their health and treatment outcomes throughout the trial.
- Data Management: Systematic collection, analysis, and reporting of trial data, ensuring compliance with regulatory standards.
Manufacturing and Quality Control
La Jolla Pharma places a strong emphasis on manufacturing excellence and quality assurance. Their approach includes:
- Regulatory Compliance: Adhering to standards set by regulatory bodies such as the FDA, ensuring that all manufacturing practices meet or exceed the required specifications.
- GMP Practices: Establishing good manufacturing practices to guarantee the consistency and quality of products before they reach the market.
Regulatory Affairs
Navigating the complex regulatory environment is crucial for biopharmaceutical companies. La Jollas regulatory affairs team focuses on:
- Liaison with Regulatory Authorities: Engaging with agencies like the FDA to facilitate the approval process.
- Submission Preparation: Compiling and submitting critical documents required for clinical trial applications and new drug applications, ensuring compliance with relevant regulations.
Commercialization
The company actively works towards the commercialization of its approved products, which involves:
- Market Strategy Development: Formulating marketing strategies that highlight the benefits and unique selling propositions of their therapies.
- Sales and Distribution: Establishing networks to ensure that products are available to healthcare providers and patients, thus improving accessibility to essential therapies.
- Collaboration with Stakeholders: Partnering with healthcare professionals, payers, and patient advocacy groups to enhance awareness of their offerings and promote their therapeutic benefits.
Conclusion
La Jolla Pharmaceutical Company is dedicated to addressing critical therapeutic needs through a robust portfolio of innovative products and comprehensive support services. By focusing on life-threatening diseases and engaging in rigorous clinical development, manufacturing excellence, regulatory navigation, and thoughtful commercialization strategies, La Jolla Pharma aims to enhance the quality of care and improve outcomes for patients who rely on their therapies.
Segments and Products
1. GIAPREZA® (Angiotensin II)
GIAPREZA® is La Jollas flagship product and is significant in the companys portfolio. This FDA-approved medication is a potent vasoconstrictor indicated specifically for treating adult patients experiencing septic shock or other forms of distributive shock. Administered via intravenous infusion, GIAPREZA® operates by increasing blood pressure in critically ill patients, thereby addressing a crucial medical need.
Mechanism of Action:
GIAPREZA® acts as an angiotensin II receptor agonist, which leads to vasoconstriction, enhancing blood flow to vital organs and potentially reducing mortality rates among patients suffering from severe hypotension.
LJPC-0118
Currently in clinical development, LJPC-0118 targets severe malaria, a disease that poses significant mortality risk, particularly in endemic regions. This product is part of La Jollas effort to meet the urgent medical needs in areas where malaria remains a critical health challenge.
Clinical Potential:
LJPC-0118 aims to improve treatment outcomes for patients suffering from severe malaria, which is characterized by high mortality rates and challenges in effective management.
Other Pipeline Products
La Jolla Pharmaceutical Company is actively engaged in expanding its pipeline beyond GIAPREZA® and LJPC-0118. Notable candidates include:
- LJPC-401: This investigational therapy focuses on conditions associated with iron overload, which can lead to severe health complications if not managed appropriately. The drug seeks to provide effective management options for autoimmune and chronic diseases characterized by excess iron levels.
- LJPC-30SA: Also centered around the treatment of severe malaria, LJPC-30SA is being investigated for its potential to increase survival rates in patients with this life-threatening infection.
- LJPC-0119: Targeting chronic kidney disease, LJPC-0119 seeks to address a significant area of unmet medical need, as chronic kidney disease affects millions globally and often leads to end-stage renal failure.
Services
La Jolla Pharmaceutical Company offers a suite of services that support the entire lifecycle of product development and commercialization:
1. Clinical Development
The company undertakes comprehensive clinical trials to evaluate the safety and efficacy of its products. This includes:
- Protocol Design: Crafting detailed clinical protocols that outline the methodology, objectives, and statistical analysis plan.
- Patient Recruitment and Monitoring: Identifying and enrolling eligible patients while continuously monitoring their health and treatment outcomes throughout the trial.
- Data Management: Systematic collection, analysis, and reporting of trial data, ensuring compliance with regulatory standards.
Manufacturing and Quality Control
La Jolla Pharma places a strong emphasis on manufacturing excellence and quality assurance. Their approach includes:
- Regulatory Compliance: Adhering to standards set by regulatory bodies such as the FDA, ensuring that all manufacturing practices meet or exceed the required specifications.
- GMP Practices: Establishing good manufacturing practices to guarantee the consistency and quality of products before they reach the market.
Regulatory Affairs
Navigating the complex regulatory environment is crucial for biopharmaceutical companies. La Jollas regulatory affairs team focuses on:
- Liaison with Regulatory Authorities: Engaging with agencies like the FDA to facilitate the approval process.
- Submission Preparation: Compiling and submitting critical documents required for clinical trial applications and new drug applications, ensuring compliance with relevant regulations.
Commercialization
The company actively works towards the commercialization of its approved products, which involves:
- Market Strategy Development: Formulating marketing strategies that highlight the benefits and unique selling propositions of their therapies.
- Sales and Distribution: Establishing networks to ensure that products are available to healthcare providers and patients, thus improving accessibility to essential therapies.
- Collaboration with Stakeholders: Partnering with healthcare professionals, payers, and patient advocacy groups to enhance awareness of their offerings and promote their therapeutic benefits.
Conclusion
La Jolla Pharmaceutical Company is dedicated to addressing critical therapeutic needs through a robust portfolio of innovative products and comprehensive support services. By focusing on life-threatening diseases and engaging in rigorous clinical development, manufacturing excellence, regulatory navigation, and thoughtful commercialization strategies, La Jolla Pharma aims to enhance the quality of care and improve outcomes for patients who rely on their therapies.